A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

Who May Qualify: - Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening. - Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening: Metformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist. - Need of intensification with basal insulin, as indicated at the discretion of the investigator. - Recorded HbA1c value ≥7% within the last 90 days prior to randomization. Who Should NOT Join This Trial: - Known or suspected hypersensitivity to study intervention(s) or related products. - Previous participation in this study. Participation is defined as signed willing to sign a consent form. - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method. - Participation (i.e., received any study intervention) in any interventional clinical study within 90 days before screening. - Any disorder which in the investigator's opinion might jeopardize participant's safety. Always talk to your doctor about whether this trial is right for you.